Dr Anand Jeyasekharan

Affiliations

• Platform Lead, Translational Research Integration & Support, Singapore Translational Cancer Consortium

• Principal Investigator, Cancer Science Institute of Singapore, National University of Singapore

• Senior Consultant (Medical Oncology), Department of Haematology-Oncology, National University Cancer Institute Singapore, National University Hospital

• Assistant Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore

• Deputy Programme Chair, NUS Centre for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore

• Programme Chair (Sarcoma and Musculoskeletal Oncology), National Cancer Institute of Singapore, National University Hospital

• Research Director, Department of Haematology-Oncology, National University Cancer Institute Singapore, National University Hospital

• Visiting Consultant, National Cancer Centre Singapore (NCCS)

• Joint Senior Principal Investigator, Institute of Molecular and Cell Biology (IMCB) - A*STAR

Profile

Dr Anand Jeyasekharan is a Principal Investigator at the Cancer Science Institute of Singapore, National University of Singapore, and a Senior Consultant Medical Oncologist in the Department of Haematology-Oncology at the National University Hospital, where his clinical practice focuses on lymphomas and rare malignancies. He obtained his medical degree from Christian Medical College, Vellore, India, and his PhD in Oncology at the University of Cambridge on a Gates Cambridge Scholarship. He then undertook specialist training in Internal Medicine and Medical Oncology at the National University Hospital, Singapore, where he has worked since. In addition to his clinical and research roles, he serves as Deputy Chair of the NUS Centre for Cancer Research and Research Director of Department of Haematology-Oncology, NUH.

Dr Jeyasekharan’s research focuses on understanding phenotypic determinants of drug sensitivity, using lymphomas, particularly diffuse large B-cell lymphoma, as a model system. His laboratory has pioneered advanced spatial biology platforms and high-dimensional immunophenotyping approaches to link tumour cell–intrinsic features with the immune contexture, thereby identifying key microenvironmental determinants of therapeutic resistance. He is a principal investigator of early-phase clinical trials in cell therapy and lymphoma and has led national initiatives to implement functional precision medicine in lymphoma, with a broader interest in scalable systems for personalised cancer therapy.